Datadog Earnings

Fourth Quarter 2019 Financial Highlights:
Revenue was $113.6 million, an increase of 85% year-over-year.
GAAP operating loss was $(2.3) million; GAAP operating margin was (2.0)%.
Non-GAAP operating income was $7.0 million; non-GAAP operating margin was 6.1%.
GAAP net income per diluted share was $0.00; non-GAAP net income per diluted share was $0.03.
Operating cash flow was $17.4 million, with free cash flow of $10.9 million.
Cash, cash equivalents, restricted cash, and marketable securities were $777.9 million as of December 31, 2019.

Full Year 2019 Financial Highlights:
Revenue was $362.8 million, an increase of 83% year-over-year.
GAAP operating loss was $(20.1) million; GAAP operating margin was (5.6)%.
Non-GAAP operating loss was $(5.4) million; non-GAAP operating margin was (1.5)%.
GAAP net loss per diluted share was $(0.12); non-GAAP net loss per diluted share was $(0.01).
Operating cash flow was $24.2 million, with free cash flow of $0.8 million.

Full Year 2020 Outlook:
Revenue between $535 million and $545 million.
Non-GAAP operating loss between $(30.0) million and $(20.0) million.
Non-GAAP net loss per share between $(0.07) and $(0.03), assuming approximately 302 million weighted average shares outstanding.

Regards,
maulik

35 Likes

Looks like a solid beat to me and shares are down over 7% from Wednesday’s close. I plan to add a bit to my 7.75% position.

Revenue was $113.6 million, an increase of 85% year-over-year vs.analysts’ $102.39 million (11% beat)

non-GAAP net income per diluted share was $0.03 vs. analysts’ -($0.02). ($0.05 beat)

Q1-2020 Revenue forecast $117-119 million vs. analysts’ $108.57 million (8.7% beat at midpoint)

non-GAAP net income per diluted share forecast -($0.02/$0.01) vs. analysts’ -($0.03)(50% beat at midpoint)

FY-2020 Revenue forecast $535-545 million vs. analysts’ $503.93 million (7.2% beat at midpoint)

non-GAAP net loss per share forecast between $(0.07) and $(0.03) vs. analysts’ -$(0.10)

12 Likes

I own a small amount of Datadog from ~$36. This ER combined with a “sell the news” reaction is tempting me to add to that position. One thing to keep in mind is the IPO lockup ends in March so there may be some pressure on the stock next month. Would definitely be a buying op on any weakness.

6 Likes